These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34326140)

  • 1. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
    Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
    Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
    Mao J; Johnson TR; Shen Z; Yamazaki S
    Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants.
    Eng H; Tseng E; Cerny MA; Goosen TC; Obach RS
    Drug Metab Dispos; 2020 Jun; 49(6):442-450. PubMed ID: 33811106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.
    Mao J; Tay S; Khojasteh CS; Chen Y; Hop CE; Kenny JR
    Pharm Res; 2016 May; 33(5):1204-19. PubMed ID: 26869174
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Tseng E; Lin J; Strelevitz TJ; DaSilva E; Goosen TC; Obach RS
    Drug Metab Dispos; 2024 Feb; ():. PubMed ID: 38408867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model.
    Ramsden D; Perloff ES; Whitcher-Johnstone A; Ho T; Patel R; Kozminski KD; Fullenwider CL; Zhang JG
    Drug Metab Dispos; 2022 Feb; 50(2):114-127. PubMed ID: 34789487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
    Xu L; Chen Y; Pan Y; Skiles GL; Shou M
    Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions.
    Chen Y; Liu L; Monshouwer M; Fretland AJ
    Drug Metab Dispos; 2011 Nov; 39(11):2085-92. PubMed ID: 21835977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of solvents on the time-dependent inhibition of CYP3A4 and the biotransformation of AZD3839 in human liver microsomes and hepatocytes.
    Aasa J; Hu Y; Eklund G; Lindgren A; Baranczewski P; Malmquist J; Turek D; Bueters T
    Drug Metab Dispos; 2013 Jan; 41(1):159-69. PubMed ID: 23073735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
    Zetterberg C; Maltais F; Laitinen L; Liao S; Tsao H; Chakilam A; Hariparsad N
    Drug Metab Dispos; 2016 Aug; 44(8):1286-95. PubMed ID: 27298338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
    Ou Y; Xu Y; Gore L; Harvey RD; Mita A; Papadopoulos KP; Wang Z; Cutler RE; Pinchasik DE; Tsimberidou AM
    Br J Clin Pharmacol; 2019 Mar; 85(3):530-539. PubMed ID: 30428505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive evaluation of liver microsomal cytochrome P450 3A (CYP3A) inhibition: comparison of cynomolgus monkey and human.
    Haarhoff ZE; Kramer MA; Zvyaga TA; Zhang J; Bhutani P; Subramanian M; Rodrigues AD
    Xenobiotica; 2017 Jun; 47(6):470-478. PubMed ID: 27498589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data.
    Rioux N; Batonga J; Colombo F; Massé J; Zouki C; Ribadeneira MD; Duan J; Bethell RC
    Xenobiotica; 2013 Jul; 43(7):592-7. PubMed ID: 23244592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
    Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
    Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Assessment Using Cytochrome P450 Time-Dependent Inhibition Assays at Single Time and Concentration in the Early Stage of Drug Discovery.
    Kosaka M; Kosugi Y; Hirabayashi H
    J Pharm Sci; 2017 Sep; 106(9):2839-2846. PubMed ID: 28483425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
    Yadav J; Korzekwa K; Nagar S
    Mol Pharm; 2018 May; 15(5):1979-1995. PubMed ID: 29608318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.